Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

Georgina V. Long*, Victoria Atkinson, Jonathan S. Cebon, Michael B. Jameson, Bernie M. Fitzharris, Catriona M. McNeil, Andrew G. Hill, Antoni Ribas, Michael B. Atkins, John A. Thompson, Wen Jen Hwu, F. Stephen Hodi, Alexander M. Menzies, Alexander D. Guminski, Richard Kefford, Benjamin Y. Kong, Babak Tamjid, Archana Srivastava, Anna J. Lomax, Mohammed IslamXinxin Shu, Scot Ebbinghaus, Nageatte Ibrahim, Matteo S. Carlino

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

173 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial'. Together they form a unique fingerprint.

Medicine & Life Sciences